Why Is Hims & Hers Health (HIMS) Stock Down -13.10% Today?
Key Takeaways
- Hims & Hers Health shares tumbled approximately 13.10% on Friday, erasing all of Thursday's FDA-driven gains and then some.
- The selloff follows a classic "buy the rumor, sell the news" pattern after an FDA advisory panel voted narrowly on Thursday to recommend easing compounding restrictions on four peptides.
- Broader healthcare-sector weakness added pressure, after HCA Healthcare's earnings highlighted a rise in uninsured patients, triggering a selloff across health-tech and telehealth names.
- Investors are reassessing the timeline for any peptide revenue impact, with formal FDA rulemaking likely stretching into 2027 or 2028 before compounding pharmacies gain unambiguous legal authority.
- Elevated short interest and lingering profitability concerns have amplified the downside, with the stock still trading well below its 52-week high of $70.43.
- Traders are now eyeing upcoming Q2 earnings on August 10 as the next major catalyst for direction.
Opening Summary
Shares of HIMS, the San Francisco-based telehealth platform operating as Hims & Hers Health, Inc., plunged approximately 13.10% in Friday's trading session, with the stock falling to around $28.45 from Thursday's close of $32.74. The steep decline marks a sharp reversal from the prior session's modest 3% gain and underscores the volatile nature of a stock that has been whipsawed by regulatory headlines, earnings disappointments, and shifting sentiment around its weight-loss and peptide strategies. The drop comes despite what was initially viewed as a favorable regulatory development, revealing the market's deeper concerns about the pace at which new opportunities will translate into actual revenue.
FDA Peptide Vote: A Narrow Win That Failed to Sustain Momentum
On Thursday, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted narrowly—8 to 6 with one abstention—to recommend adding BPC-157, KPV, and TB-500 to the 503A Bulk Drugs List, which governs which substances licensed compounding pharmacies can legally prepare. A fourth peptide, MOTS-c, passed on a 7-5-2 vote. The recommendation bucked the guidance of FDA career scientists, who had urged the committee to reject all seven peptides under review, citing scant human clinical data, unresolved safety signals, and poorly characterized chemical identities.
For HIMS, which acquired a California peptide manufacturing facility in early 2025 and has been steadily building compounding infrastructure, the panel's recommendation was broadly seen as a positive catalyst. Leerink Partners estimated the seven peptides under review could unlock a $2.2 billion annual telehealth market, with Hims & Hers potentially capturing roughly 20% of that opportunity. Shares initially surged more than 10% intraday on Thursday before paring gains to close at $32.74, up just over 3%. By Friday morning, sellers had taken full control.
Sell-the-News Meets a Reality Check on Timing
The sharp reversal reflects a sober reassessment of what the advisory vote actually means. The PCAC recommendation is non-binding; the FDA retains final authority and must still navigate a formal notice-and-comment rulemaking process that legal experts estimate will take eight to twelve months—or longer—before 503A pharmacies have unambiguous legal authority to compound these substances. Any meaningful revenue contribution from peptides for HIMS is therefore unlikely before 2027 at the earliest. For a stock that had rallied sharply in anticipation of the meeting, that extended timeline was enough to trigger aggressive profit-taking, particularly given the narrow and contentious nature of the committee vote.
Broader Healthcare Sector Weakness Compounds the Pressure
Adding to the selling pressure, the broader healthcare and health-tech sector came under strain on Friday after hospital operator HCA Healthcare reported a "negative payer mix shift" in its quarterly results, citing a rise in uninsured patients that reduced pre-tax income by an estimated $400 million. The disclosure rippled through healthcare-adjacent names, with HIMS falling alongside peers in the drug-development services and telehealth space. The concern is that a higher volume of uninsured or underinsured patients could weigh on demand across the broader healthcare ecosystem, including cash-pay telehealth platforms.
Market Context and Trading Activity
Trading volume in HIMS was significantly elevated on Friday, with more than 15 million shares changing hands during the session, well above the stock's three-month average daily volume of roughly 15 million. The stock's intraday range of approximately $29.14 to $34.57—a swing of about 16.6%—underscored the intense two-way volatility that has characterized the name throughout 2026. The move lower was not aligned with a single negative corporate announcement but rather a confluence of sector-wide anxiety, post-catalyst exhaustion, and the gravitational pull of lingering fundamental concerns including GAAP unprofitability, elevated debt of $1.8 billion, and a short interest that remains north of 31% of the float.
What Comes Next for HIMS
Attention now shifts squarely to HIMS's upcoming second-quarter earnings report, expected on August 10, where consensus estimates call for revenue of approximately $689 million and earnings per share near breakeven. Investors will be scrutinizing subscriber retention metrics, particularly among new Wegovy users, after Bank of America recently flagged early signs of higher-than-expected churn. The company's full-year guidance of $2.8 billion to $3 billion in revenue and $275 million to $350 million in adjusted EBITDA remains the benchmark against which execution will be measured. Additional regulatory clarity on peptides—including the outcome of the PCAC's second day of deliberations on the remaining three substances—and continued progress on international expansion through the pending Eucalyptus acquisition will also shape the narrative in the weeks ahead. With the stock now trading roughly 55% below its 52-week high, the risk-reward calculus remains hotly debated among analysts, whose price targets span a wide range from $21 to $40.
Trending AI Robots
For traders seeking to navigate volatile names like HIMS with a data-driven approach, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots. Tickeron provides hundreds of AI trading bots covering thousands of tickers across diverse strategies and timeframes, but only the strongest performers under current market conditions are featured in this dynamically updated section. Bots vary by strategy type, holding period, performance metrics, and traded symbols, allowing users to identify approaches aligned with their individual risk tolerance and market outlook. Explore the Trending AI Robots page to see which strategies are leading in today's market environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
HIMS in +8.12% Uptrend, advancing for three consecutive days on July 15, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where HIMS advanced for three days, in of 278 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
HIMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 264 cases where HIMS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for HIMS moved out of overbought territory on July 07, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on July 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HIMS as a result. In of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for HIMS turned negative on July 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .
HIMS moved below its 50-day moving average on July 24, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HIMS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HIMS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HIMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.577) is normal, around the industry mean (46.271). P/E Ratio (57.137) is within average values for comparable stocks, (100.082). Projected Growth (PEG Ratio) (2.155) is also within normal values, averaging (1.733). HIMS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.035). P/S Ratio (3.007) is also within normal values, averaging (116.118).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which is involved in real estate investment trusts
Industry PharmaceuticalsGeneric
Advertisement